# Evaluation of Iron Supplementation During Darbepoetin Alfa Treatment in Prophylaxis of Severe Anaemia Chemo-Induced

> **NCT00210002** · PHASE2 · TERMINATED · sponsor: **Institut Claudius Regaud** · enrollment: 55 (—)

## Conditions studied

- Neoplasms
- Anemia

## Interventions

- **DRUG:** Darbepoetin alfa (Aranesp®)
- **DRUG:** Ferric saccharose(Venofer®)

## Key facts

- **NCT ID:** NCT00210002
- **Lead sponsor:** Institut Claudius Regaud
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2003-11
- **Primary completion:** —
- **Final completion:** 2006-04
- **Target enrollment:** 55 (—)
- **Last updated:** 2006-11-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00210002

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00210002, "Evaluation of Iron Supplementation During Darbepoetin Alfa Treatment in Prophylaxis of Severe Anaemia Chemo-Induced". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT00210002. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*